extremity vascular anomaly hemangioma, vascular anomaly, bleomycin, VEGF inhibitor, bevacizumab
Conditions
Interventions
patient will be given intralesional bevacizumab(100mg/4ml) dose 1 mg/cubic centimeter by ultrasound guide,patient will be given intralesional bleomycin(1mg/ml) dose 0.6 mg/kg by fluoroscopy guide
Experimental Drug,Active Comparator Drug
Bevacizumab,bleomycin
Sponsors
Research department, faculty of medicine siriraj hospital, mahidol univerisy
Eligibility
Sex/Gender
All
Age
12 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.patient that diagnosed infiltrative lesion extremity vascular anomaly by MRI 2.tumor size > 3 cm. 3.pain score 3 points or higher from Visual analog scale (VAS) 4.age 12-80 years old 5.new case or recurrent case
Exclusion criteria
Exclusion criteria: 1. pregnant 2. allergy to contrast media 3. allergy to bleomycin or VEGF inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size at 6 and 12 months after intervention MRI | — |
Secondary
| Measure | Time frame |
|---|---|
| pain score at 6 and 12 months after intervention visual analog scale | — |
Countries
Thailand
Contacts
Public ContactChandhanarat Chandhanayingyong
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed